Nana Banerjee, PhD, President and CEO of McGraw-Hill Education, and Michael A. Metzger, President and COO of Syndax Pharmaceuticals, Inc., have been named to the Board of Trustees of (NWH).
Dr. Banerjee, who has extensive experience leading, innovating and scaling technology business globally, was named President and CEO of McGraw-Hill Education in April of 2018, and is responsible for the growth and management of its global businesses. Before that, he served as group president of Verisk Analytics, overseeing its retail businesses, joint data and development and its advanced research and analytics group. Before that he served as head of Citibank’s credit card business in the UK, and as Vice President of Marketing at GE Capital.
To honor the memory of his mother, who was a patient at NWH and spent a significant amount of time in its ICU, Dr. Banerjee and his wife Smita established the Sabita Karunes Scholarship. The scholarship--established in appreciation of the compassionate, dedicated, professional and high quality care that Mrs. Karunes received at NWH--honors her legacy as an educator by providing monetary awards to help RNs at NWH pursue Bachelor of Science Degrees in Nursing.
Dr. Banerjee, a resident of Bedford, holds a Ph.D. in applied mathematics from the State University of New York; a Master of Science degree in mathematics from the Indian Institute of Technology, Delhi; and a Bachelor of Science degree from St. Stephens College, Delhi.
Mr. Metzger has served as President and COO of Syndax Pharmaceuticals since May 2015. Before this role, he served as President and CEO, and a member of the board of directors of Regado Biosciences, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc.
Prior to that, Mr. Metzger served as Executive Vice President and COO at Mersana Therapeutics, Inc., a privately held biopharmaceutical company. Mr. Metzger has also served in a variety of senior business development positions, including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc; as Vice President of Corporate Development at Onconova Therapeutics, Inc.; and as a managing director at MESA Partners, Inc., a venture capital firm. He currently serves on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company, and Tarveda Therapeutics.
Mr. Metzger, a resident of Chappaqua, received a bachelor’s degree from George Washington University and an MBA in finance from the New York University Stern School of Business.
For more information about Northern Westchester Hospital, visit www.nwhc.net.